SLC2A1 and head and neck cancer: Our previous studies showed that plumbagin could inhibit the growth, invasion and migration of head and neck cancer by inhibiting PI3K/Akt/GLUT1, p38 MAPK, and PI3K/Akt/mTOR-mediated pathways (20–22).